Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 14/20 | 0.63 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.53 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19240154 | 0.79 | HSD17B3 (1.00) | HSD17B3NOTUMLMNAKDM4EMAPT | |
| SCHEMBL4048650 | 0.79 | HSD17B3 (0.51) | HSD17B3AVPR2LMNAMEN1KMT2A | |
| SCHEMBL4048653 | 0.79 | HSD17B3 (0.51) | HSD17B3AVPR2LMNAMEN1KMT2A | |
| SCHEMBL4798305 | 0.78 | HSD17B3 (1.00) | HSD17B3NOTUM | |
| SCHEMBL9094480 | 0.78 | LMNA (0.66) | NOTUMPOLBLMNAKDM4EMAPT | |
| SCHEMBL14084521 | 0.78 | HSD17B3 (0.80) | HSD17B3NOTUMLMNAKDM4EMEN1 | |
| SCHEMBL4796682 | 0.76 | HSD17B3 (0.78) | HSD17B3NOTUM | |
| SCHEMBL4797362 | 0.76 | HSD17B3 (0.60) | HSD17B3NOTUMPOLB | |
| SCHEMBL4796294 | 0.75 | HSD17B3 (0.67) | HSD17B3AVPR2NOTUMKDM4EMAPT | |
| SCHEMBL4799258 | 0.74 | HSD17B3 (0.80) | HSD17B3NOTUMPOLBKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885AVPR2 4155/4885NOTUM 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.